| Conserved pan-cancer microenvironment subtypes predict response to immunotherapy A Bagaev, N Kotlov, K Nomie, V Svekolkin, A Gafurov, O Isaeva, N Osokin, ... Cancer Cell 39 (6), 845-865. e7, 2021 | 822 | 2021 |
| Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells C Campbell, PT McKenney, D Konstantinovsky, OI Isaeva, M Schizas, ... Nature 581 (7809), 475-479, 2020 | 664 | 2020 |
| Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer D Hammerl, JWM Martens, M Timmermans, M Smid, AM Trapman-Jansen, ... Nature Communications 12 (1), 1-13, 2021 | 157 | 2021 |
| IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer OS Blomberg, L Spagnuolo, H Garner, L Voorwerk, OI Isaeva, E van Dyk, ... Cancer Cell, 2022 | 143 | 2022 |
| Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features A Gangaev, SLC Ketelaars, OI Isaeva, S Patiwael, A Dopler, K Hoefakker, ... Nature Communications 12 (1), 2593, 2021 | 125* | 2021 |
| Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes OI Isaeva, GV Sharonov, EO Serebrovskaya, MA Turchaninova, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 81 | 2019 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial I Nederlof, OI Isaeva, M de Graaf, RCAM Gielen, NAM Bakker, AL Rolfes, ... Nature Medicine, 1-13, 2024 | 34* | 2024 |
| Systems and methods for generating, visualizing and classifying molecular functional profiles A Bagaev, F Frenkel, N Kotlov, R Ataullakhanov, O Isaeva US Patent 11,984,200, 2024 | 28 | 2024 |
| Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response A Gangaev, EA Rozeman, MW Rohaan, OI Isaeva, D Philips, S Patiwael, ... Proceedings of the National Academy of Sciences 118 (43), e2102849118, 2021 | 22 | 2021 |
| PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial L Voorwerk, OI Isaeva, HM Horlings, S Balduzzi, M Chelushkin, ... Nature Cancer 4 (4), 535-549, 2023 | 19 | 2023 |
| Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast … OS Blomberg, K Kos, L Spagnuolo, OI Isaeva, H Garner, MD Wellenstein, ... OncoImmunology 12 (1), 2201147, 2023 | 11 | 2023 |
| Identification of differentially expressed gene modules in heterogeneous diseases O Zolotareva, S Khakabimamaghani, OI Isaeva, Z Chervontseva, ... Bioinformatics 37 (12), 1691-1698, 2021 | 11 | 2021 |
| P-stalk ribosomes act as master regulators of cytokine-mediated processes A Dopler, F Alkan, Y Malka, R van der Kammen, K Hoefakker, D Taranto, ... Cell 187 (24), 6981-6993. e23, 2024 | 1 | 2024 |
| UnPaSt: unsupervised patient stratification by differentially expressed biclusters in omics data M Hartung, A Maier, F Delgado-Chaves, Y Burankova, OI Isaeva, ... arXiv preprint arXiv:2408.00200, 2024 | 1 | 2024 |
| Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status Y Wang, GMHE Dackus, EH Rosenberg, S Cornelissen, LW de Boo, ... BMC Medicine 22 (1), 9, 2024 | 1 | 2024 |
| 474P ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer AY Lin, OI Isaeva, D Vessies, T Deger, L Voorwerk, V Geurts, H Horlings, ... Annals of Oncology 34, S380, 2023 | | 2023 |
| In silico analysis predicts a limited impact of SARS-CoV-2 variants on CD8 T cell recognition OI Isaeva, SLC Ketelaars, P Kvistborg Frontiers in Immunology 13, 891524, 2022 | | 2022 |
Pia Kvistborgsenior scientistGeverifieerd e-mailadres voor nki.nl